Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers

Inclusion criteria

• Healthy adult male and female subjects, 18-65 years of age inclusive
• BMI 18 to 32 kg/m2 inclusive
• Female subjects must be surgically sterile or postmenopausal for the past year and have a negative urine pregnancy test. Male subjects and their partners of childbearing potential must be willing to use two methods of contraception, one of which must be a barrier method (e.g. condom) for up to 90 days after the last study drug administration.
• Willing and able to remain in the clinical research unit as required by the protocol
• Willing and able to provide written informed consent prior to any study related procedures and to comply with all study requirements

Exclusion criteria

• History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
• History or presence of any disease, medical condition, or surgery, which may have an effect on drug absorption, metabolism, distribution, or excretion of the investigational product
• Laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel, and urinalysis) that the investigator believes show clinically relevant significant abnormalities for the normal reference range
• Any abnormality in the ECG (including QTc ≥450 msec) that in the opinion of the investigator increases the risk of participating in the study
• History or presence of alcoholism or drug abuse within the year prior to dosing
• Tobacco use, either current or within 3 months prior to dosing
• Use of any prescription medications or herbal remedies within 14 days prior to dosing, or use of over-the-counter medications or vitamins within 7 days prior to dosing, unless approved by the Sponsor
• Donation of whole blood within 56 days prior to the study
• Plasma donation within 7 days prior to the study
• Participation in an investigational device study or receipt of an investigational drug within 4 weeks prior to dosing
• Positive urine test for drugs of abuse
• Confirmed HIV, hepatitis B, or hepatitis C infection